<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04441502</url>
  </required_header>
  <id_info>
    <org_study_id>COVID19_OMICS</org_study_id>
    <nct_id>NCT04441502</nct_id>
  </id_info>
  <brief_title>Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic</brief_title>
  <acronym>COVID_OMICS</acronym>
  <official_title>Identification of Predictors for the Evolution of COVID-19 Related Interstitial Pneumonia by Transcriptomic and Seroproteomic Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigating group aims at performing an observational, prospective study that involves&#xD;
      the evaluation of circulating biomarkers predictive of clinical evolution in patients&#xD;
      suffering from COVID-19 disease.&#xD;
&#xD;
      In particular, the aim will be to verify whether there are transcripts or cytokines /&#xD;
      chemokines in peripheral blood, modulated differently in patients with COVID-19,&#xD;
      distinguished on the basis of the evolution towards more severe clinical pictures that&#xD;
      require patient intubation or that show signs of cardiovascular damage.&#xD;
&#xD;
      The study will be based on the transcriptional analysis of the entire genome and serum&#xD;
      protein to evaluate the expression of a broad spectrum of cytokines and chemokines. Genome&#xD;
      analysis will allow the genotype to be correlated to the identified gene expression profiles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design This observational, prospective, monocentric study will make use of the&#xD;
      recruitment of consecutive patients with COVID-19. Enrollment will last 6 months or,&#xD;
      considering the desirable drop in infections in the next few weeks, until exhaustion of&#xD;
      enrolled patients. Enrollment will be followed by 18 months dedicated to transcriptomics and&#xD;
      seroproteomics investigations, for a total duration of the study of 24 months.&#xD;
&#xD;
      All patients will receive optimal medical therapy, and will undergo laboratory or&#xD;
      instrumental examinations (chest x-ray, CT, echocardiography) as needed.&#xD;
&#xD;
      Blood samples will be taken at the entrance and then twice a week for the duration of the&#xD;
      hospitalization (generally 2-3 weeks).&#xD;
&#xD;
      Anamnesis will be noted for all patients. In addition, at all times, patients will undergo&#xD;
      clinical evaluation and the following laboratory tests, which include:&#xD;
&#xD;
        -  blood count&#xD;
&#xD;
        -  biochemistry&#xD;
&#xD;
        -  standard coagulation and thrombin generation, fibrin generation and fibrinolysis (INR,&#xD;
           PTT, D-dimer, Tissue Plasminogen Activator TPA, Plasminogen Activator Inhibitor PAI-2,&#xD;
           Plasmin-AntiPlasmin complex PAP, Thrombin activated Fibrinolysis Inhibitor TAFI,&#xD;
           Thrombin-AntiThrombin complex TAT, Prothrombin Fragment PF 1+2, Fibrinopeptide A)&#xD;
&#xD;
        -  inflammation/infection (IL-6, procalcitonin, ferritin, PCR, sCD14, TLR3 and 4, RANTES,&#xD;
           CCR3 and 4&#xD;
&#xD;
        -  other (troponin I, NT-pro-BNP, Hb1Ac). A subgroup of patients will undergo a&#xD;
           microcirculation analysis with SDF (Sidestream Dark Field imaging).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating markers for COVID-19 signature</measure>
    <time_frame>From ICU/ward admission for 8 weeks follow/up</time_frame>
    <description>Identify circulating transcripts (coding and non-coding for proteins) or cytokines and chemokines which, alone or in combination (COVID19_signature), are predictive of adverse events (death, endotracheal intubation) and the prognostic capacity of COVID19_signature in the prediction of adverse events in additional to the use of standard clinical parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID-19 signature and adverse cardiovascular events</measure>
    <time_frame>From ICU/ward admission for 8 weeks follow/up</time_frame>
    <description>Evaluate the association of COVID19_signature with adverse cardiovascular events. Adverse cardiovascular events are defined: death from cardiovascular causes, acute coronary syndrome, troponin T levels greater than the ninety-ninth percentile of the upper reference limit, stroke, cardiac arrhythmias, development of heart failure, venous thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 related coagulation pattern</measure>
    <time_frame>From ICU/ward admission for 8 weeks follow/up</time_frame>
    <description>Evaluate, in a subset of 20 patients, the characteristics of the coagulation pattern with specific tests for thrombin generation and fibrinolysis.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Covid19</condition>
  <condition>Interstitial Pneumonia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, whole blood, PBMC samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        240 patients with COVID-19 will be recruited, including up to 60 patients from the&#xD;
        intensive care and 180 from the specialized COVID19 departments of the IRCCS Policlinico&#xD;
        San Donato. The sample size is estimated based on the average length of hospitalization of&#xD;
        the patients and the maximum capacity of the clinical and laboratory units involved in the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Positivity to the test for SARS-Cov-2&#xD;
&#xD;
          3. Informed consent to enrollment in the study.&#xD;
&#xD;
          4. For Intensive Care patients: entry into the intensive unit and / or endotracheal&#xD;
             intubation for no more than 4 days.&#xD;
&#xD;
          5. For patients in the COVID19 wards: home hospitalization or emergency room for no more&#xD;
             than 4 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 18 years&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Patients with malignant neoplasm, autoimmune diseases.&#xD;
&#xD;
          4. Hospitalization as transfer from another hospital or other similar facility.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Ranucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico S. Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ekaterina Baryshnikova, PhD</last_name>
    <phone>+390252774754</phone>
    <email>ekaterina.baryshnikova@grupposandonato.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosanna Cardani, PhD</last_name>
    <phone>+390252774644</phone>
    <email>rosanna.cardani@grupposandonato.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Baryshnikova, PhD</last_name>
      <phone>+390252774754</phone>
      <email>ekaterina.baryshnikova@grupposandonato.it</email>
    </contact>
    <contact_backup>
      <last_name>Rosanna Cardani, PhD</last_name>
      <phone>+390252774644</phone>
      <email>rosanna.cardani@grupposandonato.it</email>
    </contact_backup>
    <investigator>
      <last_name>Marco Ranucci, MD FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Martelli, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimiliano M Corsi Romanelli, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekaterina Baryshnikova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosanna Cardani, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4</url>
    <description>World Health Organization. Novel coronavirus (2019-nCoV) SITUATION REPORT - 1 21 JANUARY 2020</description>
  </link>
  <reference>
    <citation>Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018 Feb;23(2):130-137. doi: 10.1111/resp.13196. Epub 2017 Oct 20.</citation>
    <PMID>29052924</PMID>
  </reference>
  <reference>
    <citation>Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, Wang Y, Guo X. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020 Feb 22;12(2):244. doi: 10.3390/v12020244.</citation>
    <PMID>32098422</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr;92(4):418-423. doi: 10.1002/jmv.25681. Epub 2020 Feb 7. Erratum In: J Med Virol. 2020 Oct;92(10):2249.</citation>
    <PMID>31967327</PMID>
  </reference>
  <reference>
    <citation>Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, Jiang YZ, Xiong Y, Li YJ, Li XW, Li H, Fan GH, Gu XY, Xiao Y, Gao H, Xu JY, Yang F, Wang XM, Wu C, Chen L, Liu YW, Liu B, Yang J, Wang XR, Dong J, Li L, Huang CL, Zhao JP, Hu Y, Cheng ZS, Liu LL, Qian ZH, Qin C, Jin Q, Cao B, Wang JW. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-1024. doi: 10.1097/CM9.0000000000000722.</citation>
    <PMID>32004165</PMID>
  </reference>
  <reference>
    <citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.</citation>
    <PMID>32132184</PMID>
  </reference>
  <reference>
    <citation>Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, Lu M, Dittmer U, Yang D. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020 May;92(5):491-494. doi: 10.1002/jmv.25709. Epub 2020 Feb 21.</citation>
    <PMID>32056249</PMID>
  </reference>
  <reference>
    <citation>Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-1751. doi: 10.1111/jth.14854. Epub 2020 May 6.</citation>
    <PMID>32302448</PMID>
  </reference>
  <reference>
    <citation>Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558-570. doi: 10.1080/22221751.2020.1736644. eCollection 2020.</citation>
    <PMID>32172672</PMID>
  </reference>
  <reference>
    <citation>Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007 Feb 1;73(3):463-9. doi: 10.1016/j.cardiores.2006.09.006. Epub 2006 Sep 19.</citation>
    <PMID>17049503</PMID>
  </reference>
  <reference>
    <citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.</citation>
    <PMID>32139904</PMID>
  </reference>
  <reference>
    <citation>Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi: 10.1056/NEJMoa1702090.</citation>
    <PMID>29365305</PMID>
  </reference>
  <reference>
    <citation>Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016 Jun 1;1(3):274-81. doi: 10.1001/jamacardio.2016.0433.</citation>
    <PMID>27438105</PMID>
  </reference>
  <reference>
    <citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.</citation>
    <PMID>32007143</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003 May 24;361(9371):1767-72. doi: 10.1016/s0140-6736(03)13412-5.</citation>
    <PMID>12781535</PMID>
  </reference>
  <reference>
    <citation>Greco S, Gorospe M, Martelli F. Noncoding RNA in age-related cardiovascular diseases. J Mol Cell Cardiol. 2015 Jun;83:142-55. doi: 10.1016/j.yjmcc.2015.01.011. Epub 2015 Jan 29.</citation>
    <PMID>25640162</PMID>
  </reference>
  <reference>
    <citation>Carrara M, Fuschi P, Ivan C, Martelli F. Circular RNAs: Methodological challenges and perspectives in cardiovascular diseases. J Cell Mol Med. 2018 Nov;22(11):5176-5187. doi: 10.1111/jcmm.13789. Epub 2018 Sep 11.</citation>
    <PMID>30277664</PMID>
  </reference>
  <reference>
    <citation>Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016 Oct;96(4):1297-325. doi: 10.1152/physrev.00041.2015.</citation>
    <PMID>27535639</PMID>
  </reference>
  <reference>
    <citation>Zhao S, Li CI, Guo Y, Sheng Q, Shyr Y. RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics. 2018 May 30;19(1):191. doi: 10.1186/s12859-018-2191-5.</citation>
    <PMID>29843589</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Marco Ranucci</investigator_full_name>
    <investigator_title>Head of Cardiothoracic and Vascular Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>thrombin generation</keyword>
  <keyword>fibrinogenesis</keyword>
  <keyword>fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04441502
org study id: COVID19_OMICS
nct id: NCT04441502
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The investigating group aims at performing an observational, prospective study that involves
      the evaluation of circulating biomarkers predictive of clinical evolution in patients
      suffering from COVID-19 disease.

      In particular, the aim will be to verify whether there are transcripts or cytokines /
      chemokines in peripheral blood, modulated differently in patients with COVID-19,
      distinguished on the basis of the evolution towards more severe clinical pictures that
      require patient intubation or that show signs of cardiovascular damage.

      The study will be based on the transcriptional analysis of the entire genome and serum
      protein to evaluate the expression of a broad spectrum of cytokines and chemokines. Genome
      analysis will allow the genotype to be correlated to the identified gene expression profiles.
Study design This observational, prospective, monocentric study will make use of the
      recruitment of consecutive patients with COVID-19. Enrollment will last 6 months or,
      considering the desirable drop in infections in the next few weeks, until exhaustion of
      enrolled patients. Enrollment will be followed by 18 months dedicated to transcriptomics and
      seroproteomics investigations, for a total duration of the study of 24 months.

      All patients will receive optimal medical therapy, and will undergo laboratory or
      instrumental examinations (chest x-ray, CT, echocardiography) as needed.

      Blood samples will be taken at the entrance and then twice a week for the duration of the
      hospitalization (generally 2-3 weeks).

      Anamnesis will be noted for all patients. In addition, at all times, patients will undergo
      clinical evaluation and the following laboratory tests, which include:

        -  blood count

        -  biochemistry

        -  standard coagulation and thrombin generation, fibrin generation and fibrinolysis (INR,
           PTT, D-dimer, Tissue Plasminogen Activator TPA, Plasminogen Activator Inhibitor PAI-2,
           Plasmin-AntiPlasmin complex PAP, Thrombin activated Fibrinolysis Inhibitor TAFI,
           Thrombin-AntiThrombin complex TAT, Prothrombin Fragment PF 1+2, Fibrinopeptide A)

        -  inflammation/infection (IL-6, procalcitonin, ferritin, PCR, sCD14, TLR3 and 4, RANTES,
           CCR3 and 4

        -  other (troponin I, NT-pro-BNP, Hb1Ac). A subgroup of patients will undergo a
           microcirculation analysis with SDF (Sidestream Dark Field imaging).
observational model: Cohort
time perspective: Prospective
measure: Circulating markers for COVID-19 signature
time frame: From ICU/ward admission for 8 weeks follow/up
description: Identify circulating transcripts (coding and non-coding for proteins) or cytokines and chemokines which, alone or in combination (COVID19_signature), are predictive of adverse events (death, endotracheal intubation) and the prognostic capacity of COVID19_signature in the prediction of adverse events in additional to the use of standard clinical parameters
measure: COVID-19 signature and adverse cardiovascular events
time frame: From ICU/ward admission for 8 weeks follow/up
description: Evaluate the association of COVID19_signature with adverse cardiovascular events. Adverse cardiovascular events are defined: death from cardiovascular causes, acute coronary syndrome, troponin T levels greater than the ninety-ninth percentile of the upper reference limit, stroke, cardiac arrhythmias, development of heart failure, venous thromboembolism
measure: COVID-19 related coagulation pattern
time frame: From ICU/ward admission for 8 weeks follow/up
description: Evaluate, in a subset of 20 patients, the characteristics of the coagulation pattern with specific tests for thrombin generation and fibrinolysis.
Serum, plasma, whole blood, PBMC samples
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Marco Ranucci, MD
role: Principal Investigator
affiliation: IRCCS Policlinico S. Donato
last name: Ekaterina Baryshnikova, PhD
phone: +390252774754
email: ekaterina.baryshnikova@grupposandonato.it
last name: Rosanna Cardani, PhD
phone: +390252774644
email: rosanna.cardani@grupposandonato.it
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
country: Italy
url: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
description: World Health Organization. Novel coronavirus (2019-nCoV) SITUATION REPORT - 1 21 JANUARY 2020
citation: Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018 Feb;23(2):130-137. doi: 10.1111/resp.13196. Epub 2017 Oct 20.
PMID: 29052924
citation: Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, Wang Y, Guo X. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020 Feb 22;12(2):244. doi: 10.3390/v12020244.
PMID: 32098422
citation: Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr;92(4):418-423. doi: 10.1002/jmv.25681. Epub 2020 Feb 7. Erratum In: J Med Virol. 2020 Oct;92(10):2249.
PMID: 31967327
citation: Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, Jiang YZ, Xiong Y, Li YJ, Li XW, Li H, Fan GH, Gu XY, Xiao Y, Gao H, Xu JY, Yang F, Wang XM, Wu C, Chen L, Liu YW, Liu B, Yang J, Wang XR, Dong J, Li L, Huang CL, Zhao JP, Hu Y, Cheng ZS, Liu LL, Qian ZH, Qin C, Jin Q, Cao B, Wang JW. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-1024. doi: 10.1097/CM9.0000000000000722.
PMID: 32004165
citation: Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.
PMID: 32132184
citation: Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, Lu M, Dittmer U, Yang D. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020 May;92(5):491-494. doi: 10.1002/jmv.25709. Epub 2020 Feb 21.
PMID: 32056249
citation: Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-1751. doi: 10.1111/jth.14854. Epub 2020 May 6.
PMID: 32302448
citation: Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558-570. doi: 10.1080/22221751.2020.1736644. eCollection 2020.
PMID: 32172672
citation: Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007 Feb 1;73(3):463-9. doi: 10.1016/j.cardiores.2006.09.006. Epub 2006 Sep 19.
PMID: 17049503
citation: Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
PMID: 32139904
citation: Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi: 10.1056/NEJMoa1702090.
PMID: 29365305
citation: Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016 Jun 1;1(3):274-81. doi: 10.1001/jamacardio.2016.0433.
PMID: 27438105
citation: Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
PMID: 32007143
citation: Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
PMID: 32031570
citation: Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:
PMID: 31986264
citation: Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003 May 24;361(9371):1767-72. doi: 10.1016/s0140-6736(03)13412-5.
PMID: 12781535
citation: Greco S, Gorospe M, Martelli F. Noncoding RNA in age-related cardiovascular diseases. J Mol Cell Cardiol. 2015 Jun;83:142-55. doi: 10.1016/j.yjmcc.2015.01.011. Epub 2015 Jan 29.
PMID: 25640162
citation: Carrara M, Fuschi P, Ivan C, Martelli F. Circular RNAs: Methodological challenges and perspectives in cardiovascular diseases. J Cell Mol Med. 2018 Nov;22(11):5176-5187. doi: 10.1111/jcmm.13789. Epub 2018 Sep 11.
PMID: 30277664
citation: Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016 Oct;96(4):1297-325. doi: 10.1152/physrev.00041.2015.
PMID: 27535639
citation: Zhao S, Li CI, Guo Y, Sheng Q, Shyr Y. RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics. 2018 May 30;19(1):191. doi: 10.1186/s12859-018-2191-5.
PMID: 29843589
responsible party type: Principal Investigator
investigator affiliation: IRCCS Policlinico S. Donato
investigator full name: Marco Ranucci
investigator title: Head of Cardiothoracic and Vascular Anesthesia and Intensive Care
mesh term: COVID-19
mesh term: Pneumonia
mesh term: Lung Diseases, Interstitial
sharing ipd: No